Clinical trial
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)
NCT04372589 is registered in ClinicalTrials.gov with University of Manitoba as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)
- Lead sponsor
- University of Manitoba
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- May 20, 2020
- Completion date
- May 17, 2021
- Enrollment
- 1,200 (actual)
- Sites
- 60
Conditions
As the registry lists them; a condition with its own page is linked.